A novel sirolimus-coated balloon (SCB) was noninferior to the best-in-class paclitaxel-coated balloon (PCB) in terms of late lumen loss (LLL) at 6 months after percutaneous coronary intervention (PCI) of in-stent restenosis (ISR) of drug-eluting stents (DES), new trial results show.